Molecular epidemiology, antifungal susceptibility, and ERG11 gene mutation of Candida species isolated from vulvovaginal candidiasis: Comparison between recurrent and non-recurrent infections.
Antifungal Agents
/ pharmacology
Candida
Candida albicans
Candida glabrata
Candida parapsilosis
Candida tropicalis
Candidiasis, Vulvovaginal
/ microbiology
Drug Resistance, Fungal
/ genetics
Ergosterol
/ pharmacology
Female
Fluconazole
/ pharmacology
Fungal Proteins
/ metabolism
Humans
Microbial Sensitivity Tests
Molecular Epidemiology
Mutation
Peptide Hydrolases
/ genetics
Phospholipases
/ genetics
Antifungal susceptibility
Candida species
ERG11 gene
Ergosterol content
Gene expression
Vulvovaginal candidiasis
Journal
Microbial pathogenesis
ISSN: 1096-1208
Titre abrégé: Microb Pathog
Pays: England
ID NLM: 8606191
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
12
02
2022
revised:
23
07
2022
accepted:
26
07
2022
pubmed:
4
8
2022
medline:
9
9
2022
entrez:
3
8
2022
Statut:
ppublish
Résumé
Vulvovaginal candidiasis (VVC) is a prevalent infection of the genitourinary tract affecting millions of women worldwide. In the present study, the importance of virulence factors, ERG11 gene mutations, ERG11 gene expression, and plasma membrane ergosterol content for fluconazole resistance in Candida species was investigated in 200 women suspected of vulvovaginitis. Isolated Candida species were identified using the ITS-restriction fragment length polymorphism (ITS-RFLP) technique. Antifungal susceptibility testing was performed according to the CLSI document. ERG11 gene expression was analyzed using real-time PCR. ERG11 gene mutation analysis was performed using sequencing methods, and the ergosterol content of the cell membrane was determined in fluconazole-resistant isolates. Furthermore, the production of phospholipase and proteinase enzymes was evaluated in recurrent and non-recurrent infections. VVC was diagnosed in 101 (50.5%) of the 200 clinical cases, of which 21 (20.8%) were confirmed as RVVC. Candida albicans was the most prevalent species, followed by C. glabrata, C. tropicalis, C. krusei, C. parapsilosis, and C. guilliermondii. Ketoconazole and fluconazole were the most effective drugs against C. albicans among five tested antifungals with MIC ranges between 0.06 and 16 μg/mL and 0.25-64 μg/mL. Substitutions of A114S, Y257H, T123I and A114V were detected in fluconazole-resistant C. albicans. The ergosterol content of the fungal cell membrane and the mean levels of ERG11 gene expression transcript were higher in fluconazole-resistant C. albicans isolates obtained from RVVC than in those obtained from VVC cases. Phospholipase and proteinase were produced in different amounts in all Candida species isolated from VVC and RVVC cases. In this review, our results demonstrated that several molecular mechanisms, including ERG11 gene expression, changes in the cell membrane ergosterol content, and mutations in ERG11 gene alone or simultaneously involved in fluconazole resistance of C. albicans species and the recurrence of VVC.
Identifiants
pubmed: 35921954
pii: S0882-4010(22)00309-6
doi: 10.1016/j.micpath.2022.105696
pii:
doi:
Substances chimiques
Antifungal Agents
0
Fungal Proteins
0
Fluconazole
8VZV102JFY
Phospholipases
EC 3.1.-
Peptide Hydrolases
EC 3.4.-
Ergosterol
Z30RAY509F
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
105696Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declarations of competing interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.